Home › Cancer (all types) › NCT04723810

TumorGlow Intraoperative Molecular Imaging (IMI)

A Study to Evaluate the Safety and Efficacy of Indocyanine Green for Intraoperative Molecular Imaging of Solid Tumors (TumorGlow™)

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

* Adult patients 18 years of age or older.
* Patients presenting with any solid tumor and/or diseased tissue even benign nodules presumed to be resectable and at risk for recurrence on pre-operative assessment.
* Good operative candidate as determined by the treating physician and/or multidisciplinary team.
* Subject capable of giving informed consent.

Exclusion Criteria:

* Subject unable to participate in the consent process.
* Vulnerable population including pregnant women, prisoners, and children.
* History of uncontrolled hypertension (e.g., history of an ER admission for hypertensive crisis or ≥ 3 blood pressure medications)
* Patients with a self-reported history of iodide allergies.

About the study

This is a Phase 1/2 study in patients presenting with any solid tumor and/or diseased tissue even benign nodules presumed to be resectable and at risk for recurrence on pre-operative assessment who are considered to be good surgical candidates to evaluate the safety and efficacy of the image-guided surgery using indocyanine green for intramolecular imaging of solid tumors.

What is being tested

• Indocyanine Green (drug)

Sponsor: University of Pennsylvania · Participants: 500 · Started: Aug 14, 2024

Contact the study team

• Azra Din · Phone: 215-615-7980

Official record on ClinicalTrials.gov — NCT04723810

Locations in the U.S.

Conditions

• Cancer (all types)

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.